Compare SLI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | EVO |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | Canada | Germany |
| Employees | N/A | 4553 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 934.1M |
| IPO Year | 2011 | N/A |
| Metric | SLI | EVO |
|---|---|---|
| Price | $3.84 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.25 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.8M | 94.1K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.49 | $2.31 |
| 52 Week High | $6.40 | $4.80 |
| Indicator | SLI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 36.25 |
| Support Level | $3.04 | $2.32 |
| Resistance Level | $4.08 | $3.78 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 27.33 | 6.44 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company the company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.